Stroke is the most common cause of death and disability from neurologic disease in humans. Activation of microglia and matrix metalloproteinases (MMPs) is involved in positively and negatively affecting stroke outcome. Novel, noninvasive, multimodal imaging methods visualizing microglial and MMP alterations were employed. The spatio-temporal dynamics of these parameters were studied in relation to blood flow changes. Micro positron emission tomography (μPET) using [
INTRODUCTION
Cerebral ischemia is followed by a variety of cellular and molecular alterations. In the cascade of molecular changes after acute cerebral ischemia inflammatory cells and proteases, such as matrix metalloproteinases (MMPs), are known to be key factors in contributing to tissue damage and also to tissue repair functions.
An important group of inflammatory cells activated as a response to ischemia are microglial cells, a subset of glial cells that constantly survey the central nervous system for pathogens and damage. Depending on the activation state, microglial cells fulfill various roles in stroke pathogenesis. Either they exhibit a detrimental function by releasing pro-inflammatory cytokines and chemotactic proteins, thereby amplifying the inflammatory reaction, or they have a beneficial function by promoting repair processes. 1 Upon activation, microglial cells express the 18-kDa mitochondrial translocator protein (TSPO) that has been identified as a characteristic marker for microglial activation. 2, 3 Microglia express a number of proteases, including the latent forms (zymogens) of MMP-2 and MMP-9, which are well characterized as key factors involved in brain damage. 4 The MMP activation has been reported to cause blood-brain barrier damage that is associated with hemorrhagic transformation after acute ischemic stroke. 5 Matrix metalloproteinases are considered to be components of the acute inflammatory reaction after stroke. 6, 7 Most importantly, MMPs are capable of modulating inflammatory and immune responses by processing signaling molecules and by affecting cell migration. 8 In agreement with these observations, early inhibition of MMP-9 activity in experimental stroke has beneficial effects on stroke outcome. 9 In contrast to acute MMP inhibition, it was also shown that late inhibition can have detrimental effects, leading to increased brain damage characterized by reductions in neurons and newly formed blood vessels. 10 Advanced in vivo imaging approaches evaluating the temporal and spatial dynamics of inflammatory alterations after stroke might improve our understanding of the different activation states of microglia and MMPs and impact on tissue outcome. This is of particular importance for the evaluation of therapeutic attempts aimed at modulating postischemic inflammation and tissue remodeling to improve clinical outcome of patients. 1 Approaches employing in vivo micro positron emission tomography (μPET) for imaging of microglial activation focus on radiolabelled compounds binding to TSPO 50 values for activated MMP-2 and -9. Due to its underlying molecular structure, [ 18 F]BR-351 can effectively bind to the activated forms of MMP-2, -8, -9, and -13, while the latent forms are not recognized.
The aims of the current study are (1) to evaluate the temporal and spatial evolution of microglia and MMP activation after focal cerebral ischemia in a mouse model of transient middle cerebral artery occlusion (tMCAo) employing [ 18 Tc ]HMPAO) and micro single photon emission computed tomography (μSPECT) as well as to structural stroke outcome as measured by T2-weighted (T2w) micro magnetic resonance imaging (μMRI).
MATERIALS AND METHODS

Study Design
Multimodality imaging based on μPET and μMRI was applied to investigate the spatial and temporal dynamics of microglial and MMP activation in a murine model of transient stroke in relation to cerebral blood flow measurements and histologic markers.
Experiments were in accordance with the German Law on the Care and Use of Laboratory Animals and approved by the Landesamt für Natur, Umwelt und Verbraucherschutz of North Rhine-Westphalia and ARRIVE guidelines. C57BL/6 mice were housed at constant temperature (23°C) and relative humidity (40%) under a regular light/dark schedule. Food and water were available ad libitum. Samples sizes were determined by power analysis during the animal ethics dossier application.
A total of N = 31 of 63 mice underwent μPET and μMRI-T2w imaging studies, respectively. An additional set of n = 14 mice were subjected to μSPECT imaging to assess the severity of focal cerebral ischemia at day 1 after tMCAo and its correlation with microglia and/or MMP activity as well as tissue outcome 14 days after tMCAo. Eighteen animals died during the experimental procedures. Fourteen mice underwent [ 99m Tc]HMPAO μSPECT at 24 hours and μMRI-T2w at 14 days, whereas n = 6 of 14 mice were assessed at days 14 and 15 by μPET using [ 18 F]BR-351 for assessment of microglia (TSPO) and MMP activity at different stages after tMCAo (24 to 48 hours (n = 8), 7 ± 1 days (n = 8), 14 ± 1 days (n = 8), 21 ± 1 days (n = 7)). T2w-μMRI was performed at the same time of μPET studies in all animals. In addition, n = 4 sham operated animals, 7 days after tCMAo, were included in the study. The experimental setup is summarized in Supplementary Figure 1 . According to this protocol, multimodal [ 18 F] DPA-714 μPET, [
18 F]BR-351 μPET, and T2w-μMRI data were available in the same animal for each time point. After each imaging time point, mice were killed. All mice with successful multimodal imaging were included in the data analysis and fixed for immunohistochemistry. No outliers were excluded from the study.
Transient Middle Cerebral Artery Occlusion Surgery
In all, N = 63, 3 to 4 months old, male C57BL/6 mice (22 to 25 g body weight) underwent right tMCAo (30 minutes), using an intraluminal occlusion model as described elsewhere with minor modifications. 12 In Figure 2) . In the sham operated animals, the filament was shortly inserted into the external common carotid artery and immediately retracted. Mice were kept under 1.5% isoflurane anesthesia in 100% oxygen throughout the procedure. Body temperature was maintained at physiologic level with a custom built heating pad.
Radiochemistry [
18 F]DPA-714 was prepared following the procedure described in the literature with a radioactive purity of 99% and a decay corrected yield (rcy) of 23 ± 5%. 13 The synthesis and quality control of [ Micro PET studies were performed on a high-resolution small animal PET scanner (32 module quadHIDAC, Oxford Positron Systems Ltd., Oxford, UK) with uniform spatial resolution ( o1 mm FWHM (full-width at halfmaximum)) over a large cylindrical field-of-view (165 mm diameter, 280 mm axial length). The μPET data were reconstructed using one-pass list mode expectation maximization algorithm with resolution recovery. After each μPET acquisition, the animal bed was transferred into the μCT scanner (Inveon, Siemens Medical Solutions, Knoxville, TN, USA) to acquire μCT images with a spatial resolution of 80 μm. The μCT images were used for anatomic coregistration with the μPET images using a landmark-based approach. In short, three molecular sieve spheres (Acros Organics, Geel, Belgium) (two on the left side and one at the right side of the animal bed) were rinsed in radiotracer solution and taped onto the animal bed. The μPET and μCT images were fused using the landmark tool of the open source image analysis software VINCI (Version: 4.19.0; http://www.nf.mpg. de/vinci3/). 16 
Magnetic Resonance Imaging Studies
The μMRI was performed with a 9.4-T small animal MR scanner with 20 cm bore size (Bios-Spec 94/20; BrukerBioSpin MRI GmbH, Ettlingen, Germany). The system was operated using the software ParaVision 5.1. (BrukerBioSpin MRI GmbH). We used the helium-cooled Cryoprobe (BrukerBioSpin MRI GmbH) to obtain anatomic 2D T2w RARE brain images in three imaging planes (28 planes, slice thickness 0.5 mm, in-plane resolution 78 μm 2 (repetition time 3,000 to 5,500 ms, echo time 50 ms, rare factor 16, 6 averages, 14 to 28 contiguous slices, slice thickness 0.5 mm, field of view 20 mm 2 , 256 matrix, in-plane resolution 78 μm 2 , scan time 5 to 9 minutes, respectively).
The μMRI was conducted for identification of stroke location, volume, and coregistration to μPET and μSPECT images.
Data Analysis
Image data were analyzed using the VINCI software. 16 The μCT images superimposed to μPET and μSPECT images were coregistered to MRI images using anatomic landmarks and 'Contour-' and 'Fusion-tool' provided by the VINCI software.
The obtained PET/CT images were superimposed to μMRI by using the automatic contour tool, reliably delineating the skull of the mice. The skull contour was further manually superimposed onto the μMRI data using anatomic landmarks. Several structures were used for optimal anatomic coregistration. Example regions were the paraflocculus region (MR) and its respective bone structure (CT); the temporomandibular joint region, the sphenoidal bone, the bulbus olfactorius region, and the lambda region (thickening of the skull dividing the visual cortex from midbrain and cerebellum on top of the inferior colliculus). All coregistrations were verified thoroughly in all 3D image planes.
For the μMRI-based analysis, VOIs were manually drawn into each slice of the coronal MR images. We segmented two different VOIs: (1) the stroke area was identified by the hyperintense signal on T2-weighted images; (2) a comparable second VOI of comparable size and location was drawn in the contralateral hemisphere. These VOIs were copied on μSPECT/μPET images for calculation of regional uptake.
The μPET data were analyzed using μMRI-based analysis, blinded for the μPET imaging results. The μPET tracer uptake was expressed as percentage of injected dose by dividing counts per milliliter in the VOI by total counts obtained in a VOI that included the entire animal, multiplied by 100 (% ID/cc). Lesion-to-contralateral ratios (L/C) were calculated between the ischemic and the contralateral control hemispheres. Hemispheric VOIs were drawn on the obtained PET/CT images of the sham group. Ipsilateral to contralateral uptake ratios (I/C) were calculated.
The μSPECT data were expressed as standardized uptake values, calculated by dividing the tissue radioactivity concentration by the injected activity multiplied by the bodyweight of the mouse.
To investigate interrelations between blood flow disturbance, microglia and MMP activity and stroke size, percentage infarct size relative to whole brain size were calculated for each mouse from the T2w-μMRI data and correlated to the percentage of remaining relative cerebral blood flow (rCBF) in the ipsilateral hemisphere. For correlation with μPET imaging parameters, the percentage of remaining rCBF in the ipsilateral hemisphere 24 hours after tMCAo was correlated to the tracer uptake (%ID) for [ 
Immunohistochemistry
After the last imaging examination, mice were killed and perfused with 4% PFA. Brains were dissected, fixed overnight in 4% PFA, embedded in paraffin and cut in 5 μm coronal sections. Immunohistochemistry was performed for all animals using the paraffin-embedded coronal brain sections employing antibodies for microglia (1:2,000, goat anti Iba-1, ab107159, Abcam, Cambridge, UK), MMP-9 (1:200, rabbit anti-mouse MMP-9, ab38889, Abcam), and TSPO (1:250, rabbit, anti-TSPO, NBP1-95674, Novus Biologicals, Cambridge, UK).
Antigen retrieval was performed by boiling the slides in citrate buffer (pH 6; 30 minutes). Slides were then treated with blocking solution for 30 minutes (1%BSA and 0.5% Triton-X in PBS), subsequently incubated (4°C, overnight) with the primary antibodies for Iba-1 (1:2,000), MMP-9 (1:200), and TSPO (1:250), respectively, followed by incubation with Alexa Fluor 488-conjugated anti-rabbit secondary antibody (1:800, A-21206, Life Technologies, Carlsbad, CA, USA), or Alexa Fluor 555 conjugated anti-goat (1:800, A-21432, Life Technologies, Carlsbad, CA, USA). For conventional histology for TSPO and MMP-9, slides were incubated with a biotinylated goat anti-rabbit (1:800, 45 minutes, B21078, Life Technologies, Darmstadt, Germany), followed by HRP-Streptavidin incubation (20 minutes, K1016, DAKO, Hamburg, Germany). Slides were incubated with 3,3-Diaminobenzidine (D-5637, Sigma, Hamburg, Germany) for 5 minutes. Sections were counterstained with hematoxylin, dehydrated, and mounted using Entellan (Merck, Darmstadt, Germany). The MMP-9 immunofluorescence was taken from the infarct core, whereas the TSPO immunfluorescence was taken from core-to-periinfarct regions.
Slides were mounted in DAPI containing mounting medium (Vectashield, H-1500, Vector Laboratories, Burlingame, CA, USA). Images were acquired with a combined fluorescence-light microscope (Nikon Eclipse NI-E, Nikon, Tokyo, Japan).
Statistical Analysis
All statistical analyses were performed using Sigma Plot 11.0 software package (Systat Software, Erkrath, Germany). Data are expressed as mean ± s.d. All comparisons were tested for normality and variance homogeneity using the Sigma Plot software. Differences between VOIs in ipsilateral and contralateral hemispheres were tested using a paired t-test, eventually followed by Mann-Whitney U-test on ranks. Overall temporal differences in radiotracer uptake were tested with a one-way analysis of variance (ANOVA) ([ 18 F]BR-351) or a Kruskal-Wallis ANOVA on ranks, followed by pairwise multiple comparison procedures (Dunn's Method/ Holm-Sidak method). Correlation analyses were performed using the Spearman correlation analyses. The interhemispheric difference in the sham group was analyzed using paired t-tests. Comparisons with the experimental group were performed with an unpaired t-test with Welch's correction.
Significance levels were set at Po0.05. HMPAO uptake ratios between the hemispheres showed an average reduction of the ipsilateral rCBF of 64.3 ± 22.2%. The degrees of perfusion deficits ranged from severe with a remaining ipsilateral rCBF reduced to less than 40% of contralateral values (n = 4) ( Figure 1A first row, B), to mild and moderate changes of remaining ipsilateral rCBF (51% to 85%; n = 10) ( Figure 1A second row, B) . T2-weighted μMRI of the same animals at 14 days after tMCAo revealed various infarct sizes, which were correlated to the severity of perfusion deficit observed at 24 hours after tMCAo (R 2 = 0.66; P = 0.003; n = 14) ( Figures 1A and 1B 18 F]DPA-714 uptake was significantly increased from day 7 (L/C: 1.77 ± 0.39; ANOVA, *P o0.05; n = 8), peaked at day 14 (L/C: 2.81 ± 0.76; ANOVA, ***P o0.001; n = 8), and was still significantly elevated 21 days after tMCAo (L/B: 2.14 ± 0.46; ANOVA, ***P o0.001; n = 7). [ 18 F]DPA-714 uptake is significantly increased in the infarct compared with the contralateral reference region at day 7 (t-test, **P40.01; n = 8), day 14 (t-test, ***P o0.001; n = 8) and day 21 (t-test, ***P o0.001; n = 7). [
RESULTS
Relative
18 F]BR-351 uptake is significantly increased in the infarct 24 to 48 hours (t-test, *P o0.05; n = 8) and 7 days (t-test, *P o0.05; n = 8) after tMCAo. Data are represented as ratio ± s.d. , and 21 days) . The μPET imaging of microglia and protease activity after tMCAo showed a timedependent increase in radiotracer uptake. For quantification of imaging data, lesion to contralateral (L/C) ratios were calculated.
In total, n = 31 animals underwent successful multitracer imaging followed by T2w-μMRI. The [
18 F]DPA-714 uptake ratio was significantly higher in the lesioned area compared with the contralateral site starting at day 7 (L/C: 1.77 ± 0.64; P o 0.001; n = 8) (Figure 2A,  Supplementary Figure 3) .
[ 18 F]BR-351 uptake in the ipsilateral hemisphere was significantly increased at 24 to 48 hours (L/C: 1.37 ± 0.19; P o 0.05; n = 8) and 7 days (L/C: 1.47 ± 0.39; P o0.05; n = 8) after tMCAo (Figures 2A to 2C) (Figure 4) . At 24 to 48 hours after tMCAo, TSPO was found in microglial cells and surrounding larger vessels in the occluded hemisphere. At 7 days, strong TSPO expression was observed in the infarct core and in adjacent areas originating from activated microglia as indicated by Iba-1 staining, and no vesselassociated TSPO staining was detected. At 14 and 21 days after tMCAo, the TSPO staining in the infarct region was more pronounced than at day 7. Double immunofluorescence staining revealed that Iba-1-positive microglia expressed TSPO (Figure 4) . No TSPO immunoreactivity could be detected in the contralateral hemisphere, except at 21 days after tMCAo, where faint TSPOpositive endothelial cells could be found. We could not detect any evidence for astrocytes contributing to the TSPO signal using GFAP staining (data not shown).
Immunohistochemistry for MMP-9 confirmed the dynamics of [ 18 F]BR-351 tracer binding (Figure 4 ). Early after tMCAo (24 to 48 hours), endothelial and microglial cells showed positive staining for MMP-9, whereas at 7, 14, and 21 days after tMCAo the MMP-9 signal was seen in some positive but also in Iba-1-negative cells. Some of these MMP-9 immunoreactive cells were apoptotic cells according to their fragmented nuclei (data not shown). In all animals where μPET was negative for [ 18 Figure 4A, D) . There was no increased binding of 
DISCUSSION
This is the first multitracer μPET imaging study investigating the temporal and spatial relationship of two critical inflammatory markers after focal cerebral ischemia in vivo. Our results suggest a The cellular and subsequent neuroinflammatory response to ischemic damage is characterized by infiltrating monocytes/ macrophages and activation of resident microglia. 17 Activation of microglia involves upregulation of the peripheral benzodiazepine receptor named TSPO. 2, 3 Translocator protein is an important mitochondrial target for assessment of neuroinflammation since under physiologic conditions basal expression levels are low (microglia, astrocytes, endothelial and smooth muscle cells, subpial glia, intravascular monocytes, and ependymal cells). In contrast, it is highly upregulated after a neuroinflammatory stimulus in glial cells (microglia, astrocytes) and macrophages. 1, 3, 18, 19 In the past 30 years, various TSPO ligands have been designed to study microglia-based neuroinflammation in vivo.
1 One of the most important TSPO radiotracers used is Images were taken from infarcted areas indicated by the white cross in Figure 2 . MMP-9 immunohistochemistry was taken from the infarct core, and TSPO immunohistochemistry from a core-to-periinfarct region, since the massive expression of TSPO in the infarct core did not allow to distinguish single cells. TSPO expression within the infarct is time dependent: 24 to 48 hours after transient middle cerebral artery occlusion (tMCAo) the density of TSPO expressing cells is relatively low, compared with later time points. TSPO was also localized surrounding some larger vessels in the ipsilateral hemisphere at this time. At 7 and 14 days, TSPO staining increased in density with colocalization with microglia cells as defined by Iba-1 staining and morphology. The TSPO signal correlated to the imaging data derived from [ 18 F]BR-351 μPET data, MMP-9 staining was found in the infarct area at 24 to 48 hours after tMCAo in association with the vasculature and microglia (Iba-1), and after 7 days in activated microglia and apoptotic cells. At later time points (14 and 21 days after tMCAo), MMP-9 was mainly found in apoptotic cells. All images were taken with the same magnification. Scale bar: 100 μm. ]DPA-714 has a relatively low brain uptake under standard physiologic conditions and improved bioavailability, higher specificity, and favorable signal-to-noise ratios in selected disease models. 18, 20 This, together with the advantage of a longer half-life of the positron emitter fluorine-18 radio isotope, makes [ In the current investigation, [ 18 F]DPA-714 μPET imaging revealed a time-dependent increase in uptake in the infarcted region starting from day 7 up to day 21 after tMCAo with a peak at 14 days. This is in agreement with the findings of Martín et al 21 that showed increased [
18 F]DPA-714 binding in the ipsilateral hemisphere at day 7, peaking at day 11 after tMCAo, 21 and with an autoradiographic ex vivo study in mice showing the highest [ 3 H] DPA-714 binding at day 14 after tMCAo. 22 However, in the latter study only days 1, 3, and 14 after tMCAo were analyzed. 22 In contrast to our study, where DPA-714 uptake was related to the severity of postischemic hypoperfusion ( It has been reported that not only microglia but also astroglia contribute to the TSPO signal, 19, 21 although in stroke, microglial cells seem to be the main source of TSPO expression. We did not detect TSPO-positive astrocytes at any of the time points using immunohistochemical analyses.
Also, another study in an Alzheimer's disease mouse model showed that TSPO upregulation in microglial cells was associated with deleterious neuronal damage, whereas TSPO expression in astrocytes was an indicator of neurotrophic support. 23 It should be pointed out that currently all TSPO tracers including [
18 F]DPA-714 cannot distinguish between the different microglial phenotypes (primed, neurotoxic, neuroprotective, others) in vivo. For this purpose, the development of new microglia phenotype-specific probe/target combinations is necessary. Interestingly, we found that microglial activation as measured by [ 18 F]DPA-714 was related to the extent of perfusion deficits as assessed by [
99m Tc] HMPAO μSPECT 24 hours after tMCAo suggesting that the severity of ischemia may be the stimulus for microglia activation. It should be pointed out that hemodynamic changes 24 and inflammatory alterations 25 within the contralateral hemisphere may have led to an underestimation of L/B ratios. Furthermore, it has been shown that T2 values can resolve to normal values or increase depending on the type of lesion, i.e., initial cortical or no cortical involvement. 26 This might have led to underestimation of μPET quantification parameters at time point 47 days. MMPs have been shown to be key players in stroke pathogenesis. They are associated with blood-brain barrier damage, hemorrhagic transformation, and vasogenic edema formation. 7, 27, 28 Over-simplification of MMPs as purely extracellular matrix degrading enzymes should be avoided since in vivo evidence that MMPs degrade extracellular matrix is lacking. 29 MMPs have been shown to be involved in modulating inflammatory and immune responses both positively and negatively by processing signaling molecules and by affecting cellular migration. 8 As an example, IL-1ß and TNF-alpha released by microglia/macrophages are tightly regulated by MMPs. 30 Several approaches have been undertaken to study MMPs in stroke and other pathologies in vivo. [31] [32] [33] [34] [35] [36] In the case of cerebral ischemia, studies to date have exclusively used MMP-activatable near-infrared MMPSense fluorescent probes. 36, 37 However, nearinfrared imaging have low tissue penetration and the inability to correct for scatter and attenuation making it unsuitable for clinical application. Therefore, in our study we used the newly developed radiofluorinated hydroxamate-based MMP inhibitor [
18 F]BR-351, which is based on CGS27023A 125966 and binds to activated forms of MMP-2 (IC 50 = 4 nmol/L), -8 (2 nmol/L), -9 (50 nmol/L), and -13 (11 nmol/L). 38 [ 18 F]BR-351 uptake was observed to be increased in the infarct VOI as early as 24 to 48 hours after tMCAO reaching a maximum at 7 days. No significant differences between the time points analyzed thereafter could be identified using pairwise comparisons. This is in accordance with the previous findings showing that activated MMP-9 can be detected at 12 to 24 hours after permanent MCAo in mice, 39 rats, 9 and non-human primates. 5 In these studies, MMP-9 activity was reported to peak 24 hours after MCAo with levels persisting for 5 days, and basal levels being reestablished at 15 days. In contrast to MMP-9, zymographic analyses of MMP-2 expression indicated persisting low level expression up to 30 days after tMCAo. 9 It should be pointed out that various cell types seem to contribute to MMP-9 expression after stroke. 9 The investigation of the cellular source of MMPs was not in the scope of the work, but the analysis of the relation between MMP-9 activity with regards to microglia activity as assessed by Iba-1. Early after tMCAo, MMP-9 has been reported in association with endothelial cells and neutrophils, 9,10 whereas after 7 days microglial cells have been reported to express MMP-9. 9 Other studies suggest that astrocytes and neurons are also MMP-9 positive after 7 and 14 days. 10 Moreover, in our study at 7 days after tMCAo MMP-9 expression was found in cells with fragmented nuclei (Figure 4) suggesting an associated role in apoptotic processes or to cells undergoing secondary necrosis. 40 99m Tc]HMPAO images 24 hours after tMCAo suggested variable reductions of rCBF in the ipsilateral hemisphere, which is in accordance with recent data obtained in rats 2 hours after tMCAo. 43 Also, the latter model of perfusion imaging employing [ 13 N]Ammonia showed initial ipsilateral hypoperfusion with rCBF reductions to 40%, followed by normalization and hyperperfusion. 43 Possible explanations for persisting rCBF disturbances after transient MCAo could be that (1) the surgical procedure itself leads to thrombus formation and secondary infarctions due to endothelial damage; (2) upregulation of contractile receptors (e.g., endothelin B) leads to vasoconstriction after tMCAo; 44 and (3) metabolic 45 disturbances and/or oxidoreductive states 46 24 hours after tMCAo affect the conversion of [ 99m Tc]HMPAO from a lipophilic to a hydrophilic derivative, independent of blood flow. The postischemic hypoperfusion 24 hours after tMCAo can further be attributed to the 'no-reflow phenomenon'. It has been related to the narrowing of capillaries 47 and loss of both arteriolar dilating mechanisms and cerebrovascular reactivity. 48 Taken together, the mechanisms of tracer uptake of [
99m Tc] HMPAO may not exclusively be perfusion dependent. Pathologic conditions like cerebral ischemia lead to complex molecular, cellular, and physiologic alterations, which could influence tracer uptake and which have to be considered in the interpretation of 
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